Savara Announces Acceptance Of Abstract For Poster Presentation At European Respiratory Society Congress 2024 In Vienna; Will Present Results From IMPALA-2 Study On Inhaled Molgramostim For Autoimmune Pulmonary Alveolar Proteinosis And Sponsor An Industry Symposium
Portfolio Pulse from Benzinga Newsdesk
Savara announced the acceptance of an abstract for a poster presentation at the European Respiratory Society Congress 2024 in Vienna. The company will present results from the IMPALA-2 study on inhaled Molgramostim for autoimmune pulmonary alveolar proteinosis and sponsor an industry symposium.
August 15, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Savara will present results from the IMPALA-2 study on inhaled Molgramostim at the European Respiratory Society Congress 2024, which could increase visibility and investor interest.
The acceptance of the abstract and the presentation at a major congress can increase the visibility of Savara's research and potentially attract investor interest, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100